SOX2 regulates paclitaxel resistance of A549 non-small cell lung cancer cells via promoting transcription of ClC-3
Sign Up to like & getrecommendations! Published in 2022 at "Oncology Reports"
DOI: 10.3892/or.2022.8396
Abstract: Paclitaxel (PTX) is widely used in the treatment of non-small cell lung cancer (NSCLC). However, acquired PTX drug resistance is a major obstacle to its therapeutic efficacy and the underlying mechanisms are still unclear. The… read more here.
Keywords: ptx resistance; resistance a549; clc; resistance ... See more keywords